Demand for safe packaging to combat illicit drug market rackets on the rise
Pharma manufacturers are feeling encouraged to explore new possibilities.
Future Market Insights offers key insights on the global anti-counterfeit pharmaceutical packaging market in a new report titled, "Anti-counterfeit Pharmaceutical Packaging Market: Global Industry Analysis and Opportunity Assessment, 2016-2026". The global anti-counterfeit pharmaceutical packaging market is projected to register a robust CAGR of 12.1% during the forecast period 2016-2026. The report provides in-depth information on the global anti-counterfeit pharmaceutical packaging market pertaining to the market trends, competitive landscape, market dynamics, and market estimation and forecast for the projected ten-year period.
Demand for safe packaging to combat illicit drug market rackets spread across the globe is increasing. The present market is plagued by forged pharmaceutical formulas. The soaring market size of counterfeit drugs is creating a parallel economy in the global market. The emerging threat has a rippling effect on all the stakeholders as well as on the consumers. This dark underbelly of the pharmaceutical industry is crippling the growth of the market. The increasing dominance of counterfeit drugs has compelled pharma manufacturers to set up a safety ring to guard them against this threat. Anti-counterfeiting packaging is one of the measures that pharma majors are relying on. They are also using conventional solutions such as integrating authentication overt features with covert elements, forensics, and track & trace elements. These measures have fetched fruitful results for pharmaceutical companies and tier II pharma organisations in the recent past. Mushrooming popularity of anti-counterfeit pharmaceutical packaging technology is affecting the global demand for anti-counterfeit pharmaceutical packaging.
The efforts of WHO and FDA to ensure safe-conduct practices across the pharmaceutical industry value chain by integrating advanced anti-counterfeit packaging technology has encouraged pharma manufacturers to explore new possibilities. This, in turn, is creating value for suppliers of anti-counterfeit packaging technology to the pharmaceutical industry. The global anti-counterfeit pharmaceutical packaging market is responding with a positive growth rate, which is likely to continue during the forecast period.
Segmentation highlights
The global anti-counterfeit pharmaceutical packaging market is segmented on the basis of usage feature (convert features, divert features, forensic markers, tamper evidence and track & trace technologies [sterilization and identification system]) and technology (RFID [active tags, passive tags, semi-active tags], security inks and coatings, security printing and graphics, hologram, mass encoding [Barcode Application, Digital Mass Serialization, Digital Mass Encryption], others [Electromagnetic, surveillance technologies]).
Regional market projections
The report covers the global anti-counterfeit pharmaceutical packaging market across seven key regions namely - North America, Latin America, Western Europe, Eastern Europe, Japan, Asia Pacific Excl. Japan (APEJ), and the Middle East and Africa (MEA). On the basis of region, North America region is projected to remain dominant in the global anti-counterfeit pharmaceutical packaging market throughout the forecast period. Anti-counterfeit pharmaceutical packaging market in North America is expected to take a major leap within the forecast period given the active presence of major pharma companies, swelling exports and several biologics research hubs that are likely to expedite market growth.
Anti-counterfeit pharmaceutical packaging is expected to witness robust growth in the APAC market driven by increasing demand for anti-counterfeit measures in the region and the market is growing at the CAGR of 18.9 % over the forecast period. In MEA region the new wave of economic reforms is wooing foreign investors. Africa is an emerging economy that is influencing local as well as international players. The anti-counterfeit pharmaceutical market in Middle East & Africa is estimated to expand at a fast-paced CAGR of 11.5% by 2026 owing to the staggering growth in the economy of the region.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance